Publication: Assessment of treatment effect with multiple outcomes in 2 clinical trials of patients with Duchenne muscular dystrophy (DMD)
This research letter, published in the JAMA Network Open, presents an analysis of two randomized, double-blind, placebo-controlled trials of a mutation-specific DMD gene therapy
A statistical analysis to evaluate the totality of evidence was conducted combing data across primary (6MWD) and secondary (timed function test [TFT]) endpoints from the phase 2b and phase 3 trials of a mutation-specific DMD therapy
Li D, McDonald CM, Elfring GL, et al. JAMA Netw Open. 2020;3(2):e1921306
Once registered, you will be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
US-DMD-0263 | April 2023
Sign in or register to access exclusive content on this site
Register here to access the content on the site US-CORP-0330 | July 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.